Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
NASDAQ:MBRX
MBRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.40 - $6.23
Previous CloseN/A
Volume63.82K
Average Volume (3M)11.33M
Market Cap
$16.10M
Enterprise Value$1.94M
Total Cash (Recent Filing)$7.13M
Total Debt (Recent Filing)$304.00K
Price to Earnings (P/E)―
Beta2.48
Next Earnings
May 08, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.12
Shares Outstanding14,000,494
10 Day Avg. Volume777,364
30 Day Avg. Volume11,325,313
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)136.34
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.13
Forecast
1Y Price Target
$13.33Price Target Upside1145.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Moleculin Biotech News
PremiumCompany Announcements
Moleculin Biotech’s Promising Earnings Call Highlights
PremiumCompany Announcements
Moleculin Biotech Advances Clinical Trials Amid Financial Losses---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe planned Phase 3 'MIRACLE' trial is based on positive Phase 1b/2 results, which showed promising complete remission rates in patients with previous treatment lines, bolstering confidence in Annamycin's potential.
Drug CharacteristicsAnnamycin is differentiated from other anthracyclines for not showing cumulative cardiotoxicity, which limits long-term use of other anthracyclines.
Regulatory ApprovalAnnamycin currently has Fast Track and Orphan Drug Designation from the FDA for the treatment of R/R AML, increasing potential to accelerate its timeline for approval.
Bears Say
Commercial TimelinesThe commercial timelines for Annamycin in acute myeloid leukemia have been pushed out to 2029 due to extended trial timelines.
Financial ChallengesThe company's cash reserves are low with high quarterly cash burn, necessitating immediate capital raising efforts.
Stock DilutionThe company is seeking to raise capital through the sale of common stock and warrants, which could lead to significant share dilution and affect the company's ability to operate.
---
Ownership Overview
0.68% Insiders
0.39% Mutual Funds
2.42% Other Institutional Investors
96.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $0.40 and its highest was $6.23 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $16.10M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is May 08, 2025 which is in 42 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Mar 24, 2025. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of -$1.283 by $1.533.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -0.56.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 14,000,494 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of $0.25 in its last earnings report, beating expectations of -$1.283. Following the earnings report the stock price went down -2.752%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
---
Company Description
Moleculin Biotech
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
---
MBRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Moleculin Biotech, emphasizing the promising data from the Phase 2 trial of Annamycin and the initiation of the MIRACLE Phase 3 trial. The company's solid financial position and clear focus on future milestones are also highlighted. However, there are challenges related to delayed enrollment in the US and the high cost of the Phase 3 trial.Read More>---
MBRX Stock 12 Month Forecast
Average Price Target
$13.33
▲(1145.79% Upside)
Technical Analysis
Cyclacel Pharmaceuticals
―
Medicinova
―
Immunic
―
Citius Pharmaceuticals
―
Atea Pharmaceuticals
―
Best Analysts Covering MBRX
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-49.47%
assigned a buy rating 3 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -49.47% per trade.
---